Liver function study tests new Drug's safety in 24 volunteers
NCT ID NCT07551557
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This early-stage study looks at how a single 25 mg dose of VC005 tablets behaves in people with mild or moderate liver impairment compared to healthy volunteers. The goal is to measure drug levels and safety. 24 participants will take one dose and be monitored closely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Bengbu Medical University
RECRUITINGBengbu, Anhui, 233000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver health and drug processing: a closer look at casdatifan
- Liver function may change how belapectin works in the body
- Liver function may change how ammoxetine works
- Liver function may affect how Weight-Loss drug petrelintide works
- Liver health may change how a promising cancer drug works in the body
- Liver health may change how body handles inhaled lung drug